Recently, a S1P1 modulator, cenerimod, demonstrated promising signals in a lupus trial at lymphocyte‐reducing doses [7], raising the question about relative contributions of lymphocyte‐reducing and endothelial‐protective mechanisms to the effects observed. Here, S1PR1 is linked to systemic lupus erythematosus.